Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2.

A systematic analysis reveals that out of 20 protein kinases examined, specific for either Ser/Thr or Tyr, the majority are extremely sensitive to staurosporine, with IC50 values in the low nanomolar range. A few of them however, notably protein kinases CK1 and CK2, mitogen-activated protein (MAP) kinase and protein-tyrosine kinase CSK, are relatively refractory to staurosporine inhibition, exhibiting IC50 values in the micromolar range. With all protein kinases tested, namely PKA, CK1, CK2, MAP kinase (ERK-1), c-Fgr, Lyn, CSK and TPK-IIB/p38Syk, staurosporine inhibition was competitive with respect to ATP, regardless of its inhibitory power. In contrast, either uncompetitive or noncompetitive kinetics of inhibition with respect to the phosphoacceptor substrate were exhibited by Ser/Thr and Tyr-specific protein kinases, respectively, consistent with a different mechanism of catalysis by these two sub-families of kinases. Computer modeling based on PKA crystal structure in conjunction with sequence analysis suggest that the low sensitivity to staurosporine of CK2 may be accounted for by the bulky nature of three residues, Val66, Phe113 and Ile174 which are homologous to PKA Ala70, Met120 and Thr183, respectively. In contrast these PKA residues are either conserved or replaced by smaller ones in protein kinases highly sensitive to staurosporine inhibition. On the other hand, His160 which is homologous to PKA Glu170, appears to be responsible for the unique behaviour of CK2 with respect to a staurosporine derivative (CGP44171A) bearing a negatively charged benzoyl substituent: while CGP44171A is 10- 100-fold less effective than staurosporine against PKA and most of the other protein kinases tested, it is actually more effective than staurosporine for CK2 inhibition, but it looses part of its efficacy if it is tested on a CK2 mutant (H160D) in which His160 has been replaced by Asp. It can be concluded from these data that the catalytic sites of protein kinases are divergent enough as to allow a competitive inhibitor like staurosporine to be fairly selective, a feature that can be enhanced by suitable modifications designed based on the structure of the catalytic site of the kinase.

[1]  P. James,et al.  Hierarchical phosphorylation of a 50-kDa protein by protein tyrosine kinases TPK-IIB and C-Fgr, and its identification as HS1 hematopoietic-lineage cell-specific protein. , 1995, European journal of biochemistry.

[2]  R M Sweet,et al.  Crystal structure of casein kinase‐1, a phosphate‐directed protein kinase. , 1995, The EMBO journal.

[3]  E. Krebs,et al.  Substrate recognition by casein kinase‐II: The role of histidine‐160 , 1994, FEBS letters.

[4]  B. Kemp,et al.  Insights into autoregulation from the crystal structure of twitchin kinase , 1994, Nature.

[5]  Elizabeth J. Goldsmith,et al.  Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution , 1994, Nature.

[6]  L. Pinna,et al.  Design and synthesis of two new peptide substrates for the specific and sensitive monitoring of casein kinases-1 and -2. , 1994, Biochemical and biophysical research communications.

[7]  Doriano Fabbro,et al.  Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C , 1994 .

[8]  F. Marks,et al.  Elongation factor‐2 kinase: effective inhibition by the novel protein kinase inhibitor rottlerin and relative insensitivity towards staurosporine , 1994, FEBS letters.

[9]  P. James,et al.  Isolation and identification of two proto-oncogene products related to c-fgr and fyn in a tyrosine-protein-kinase fraction of rat spleen. , 1993, European journal of biochemistry.

[10]  Sung-Hou Kim,et al.  Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.

[11]  Stefan Fischer,et al.  Spleen protein tyrosine kinases TPK‐IIB and CSK display different immunoreactivity and opposite specificities toward c‐src‐derived peptides , 1992, FEBS letters.

[12]  A. Brunati,et al.  Selective effect of poly(lysine) on the enhancement of the lyn tyrosine protein kinase activity. Increased specificity toward src peptides. , 1992, European journal of biochemistry.

[13]  D. Knighton,et al.  Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.

[14]  J. Zheng,et al.  Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.

[15]  Stefan Fischer,et al.  Stimulation by NaCl, polylysine and heparin of two forms of spleen tyrosine protein kinase immunologically related with the protein expressed by lyn oncogene. , 1991, Biochimica et biophysica acta.

[16]  Hideyuki Yamamoto,et al.  Staurosporine: An Effective Inhibitor for Ca2+/Calmodulin‐Dependent Protein Kinase II , 1991, Journal of neurochemistry.

[17]  G. Powis,et al.  Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine. , 1990, The Journal of biological chemistry.

[18]  L. Pinna.  Casein kinase 2: an 'eminence grise' in cellular regulation? , 1990, Biochimica et biophysica acta.

[19]  J. Herbert,et al.  Characterization of specific binding sites for [3H]-staurosporine on various protein kinases. , 1990, Biochemical and biophysical research communications.

[20]  U. Ruegg,et al.  Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases , 1989 .

[21]  D. Fabbro,et al.  A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activity , 1989, International journal of cancer.

[22]  S. Kathuria,et al.  Characterization of receptor tyrosine-specific protein kinases by the use of inhibitors. Staurosporine is a 100-times more potent inhibitor of insulin receptor than IGF-I receptor. , 1988, Biochemical and biophysical research communications.

[23]  H. Iba,et al.  Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60. , 1987, The Journal of antibiotics.

[24]  T. Tamaoki,et al.  Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. , 1986, Biochemical and biophysical research communications.

[25]  L. Pinna,et al.  Endogenous phosphate acceptor proteins for rat liver cytosolic casein kinases. , 1981, The Journal of biological chemistry.

[26]  J. Feramisco,et al.  Isolation of phosphorylated peptides and proteins on ion exchange papers. , 1978, Analytical biochemistry.

[27]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[28]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[29]  J. A. Traugh,et al.  Casein kinase I and II--multipotential serine protein kinases: structure, function, and regulation. , 1991, Advances in second messenger and phosphoprotein research.

[30]  J. Casnellie.  Assay of protein kinases using peptides with basic residues for phosphocellulose binding. , 1991, Methods in enzymology.